©2022 Stanford Medicine
A Study of Galcanezumab in Participants With Chronic Cluster Headache
Recruiting
Trial ID: NCT02438826
Purpose
The main purpose of this study is to evaluate the efficacy of the study drug known as
galcanezumab in participants with chronic cluster headache.
Official Title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
Eligibility
Inclusion Criteria:
- Participants with a history of chronic cluster headache occurring without a remission
period, or with remissions lasting <1 month, for at least 1 year.
- Participants are able to distinguish cluster headache attacks from other headaches.
Exclusion Criteria:
- Current enrollment in or discontinuation within the last 30 days from, a clinical
trial involving any investigational drug or device.
- Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP)
antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).
- Are taking indomethacin and/or are suspected of having another distinct trigeminal
autonomic cephalalgia.
- A history of migraine variants that could implicate or could be confused with
ischemia.
- Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
proteins.
- A history or presence of other medical illness that indicates a medical problem that
would preclude study participation.
- Evidence of significant active or unstable psychiatric disease, in the opinion of the
investigator.
- Women who are pregnant or nursing.
Intervention(s):
drug: Placebo
drug: Galcanezumab 300 mg
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
650-723-5184